Real-World Evidence Study on AbeMaciclib Treatment Patterns and Effectiveness in Patients with HR+/HER2- Locally Advanced or Metastatic BReAst CancEr in Kuwait and Lebanon.
- Conditions
- locally advanced or metastatic breast cancerBreast CancerT51.2
- Registration Number
- LBCTR2022035014
- Lead Sponsor
- Eli Lilly
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 100
Inclusion criteria
Patients eligible for inclusion in this study have to fulfill all of the following criteria:
1. Adult breast cancer female patients =18 years old at the start of receiving Abemaciclib,
whether as a single-agent treatment or combination treatment
2. Premenopausal or postmenopausal patients with histologically proven HR-positive,
HER2-negative with locally advanced or metastatic breast cancer (De-novo or
recurrence/progression of early breast cancer)
3. Patients who are being treated or have been treated with Abemaciclib (VERZENIO™),
whether as a single-agent treatment or combination treatment, for at least three months
before data collection
4. Patients treated with Abemaciclib (VERZENIO™), whether as a single-agent treatment
or combination treatment, according to the SmPC.
Exclusion criteria
1. Patients previously included in Abemaciclib clinical trial
2. Patients with evidence of other prior second primary concurrent malignancy apart from
locally advanced or metastatic breast cancer.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method